30482-25-8

Usage

Uses

Used in Pharmaceutical Industry:
8-Aminomethyl-1,4-dioxaspiro[4.5]decane is used as a key intermediate in the synthesis of brain-penetrating cathepsin S inhibitors. Cathepsin S is a lysosomal cysteine protease that has been implicated in various neurological disorders and diseases, such as Alzheimer's, Parkinson's, and multiple sclerosis. By inhibiting the activity of cathepsin S, these inhibitors can potentially help in the treatment and management of these conditions.

InChI:InChI=1/C9H17NO2/c10-7-8-1-3-9(4-2-8)11-5-6-12-9/h8H,1-7,10H2

Upstream product

• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 30482-24-7 1,4-dioxaspiro<4,5>decane-8-carboxamide 
• 147767-55-3 (1,4-dioxaspiro[4.5]dec-8-yl)methyl methanesulfonic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 42949-24-6 1-azaadamantane-4-one 
• 423116-18-1 2-[(4-oxocyclohexyl)methyl]isoindoline-1,3-dione 
• 869895-16-9 benzyl 1,4-dioxaspiro[4.5]dec-8-ylmethylcarbamate 
• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 869895-17-0 benzyl (4-oxocyclohexyl)methylcarbamate 
• 478841-18-8 2-((4-hydroxycyclohexyl)methyl)isoindoline-1,3-dione 
• 867023-69-6 4,5,6,7-tetrahydro-2H-indazol-5-ylmethanamine 

Relevant academic research and scientific papers

A short synthesis of 1-azaadamantan-4-one and the 4r and 4s isomers of 4-amino-1-azaadamantane

Reductive homologation of 1,4-cyclohexanedione monoethylene acetal (1) with tosylmethylisocyanide and subsequent reduction with lithium aluminum hydride gave 1,4-dioxaspiro[4.5]decan-8-yl-methylamine (3) which was converted to 1-azatricyclo[3.3.1.13,7] decan-4-one (4) via a known double-Mannich condensation. Reductive amination of this ketone gave the corresponding 1-azatricyclo[3.3.1.13,7]decan-4 (s and r)-amines (9 and 10) which were separated on a multigram scale as their corresponding tosylamides 7 and 8, followed by deprotection.

Abolishing Dopamine D2long/D3Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H2Receptor Agonists

3-(2-Amino-4-methylthiazol-5-yl)propyl-substituted carbamoylguanidines are potent, subtype-selective histamine H2receptor (H2R) agonists, but their applicability as pharmacological tools to elucidate the largely unknown H2R functions in the central nervous system (CNS) is compromised by their concomitant high affinity toward dopamine D2-like receptors (especially to the D3R). To improve the selectivity, a series of novel carbamoylguanidine-type ligands containing various heterocycles, spacers, and side residues were rationally designed, synthesized, and tested in binding and/or functional assays at H1-4and D2long/3receptors. This study revealed a couple of selective candidates (among others31and47), and the most promising ones were screened at several off-target receptors, showing good selectivities. Docking studies suggest that the amino acid residues (3.28, 3.32, E2.49, E2.51, 5.42, and 7.35) are responsible for the different affinities at the H2- and D2long/3-receptors. These results provide a solid base for the exploration of the H2R functions in the brain in further studies.

PYRIDINYL PYRAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT

The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.

2-(Bicyclo)alkylamino-derivatives as mediatores of chronic pain and inflammation

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

A general synthetic approach to novel conformationally restricted arginine side chain mimetics

A general synthesis of several novel partially saturated, conformationally restricted heterobicyclic arginine side chain mimetics is described. These compounds are interesting peptidomimetic building blocks for incorporation into trypsin-like serine protease inhibitors.

Synthesis of some unsymmetrical bridged terpyridines

Novel unsymmetrical terpyridines 1 and 2 are synthesized using intra- and intermolecular Michael additions as the key reactions, followed by the construction of the central pyridine ring. Terpyridine 1 represents a heretofore unknown hexacyclic ring system.

Novel bicyclic lactam inhibitors of thrombin: Potency and selectivity optimization through P1 residues

Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the P1 residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo.